Halozyme Therapeutics Inc. (NASDAQ:HALO)’s share price fell 1.6% on Monday . The company traded as low as $10.13 and last traded at $10.32, with a volume of 353,191 shares. The stock had previously closed at $10.49.

A number of brokerages have weighed in on HALO. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $15.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, June 9th. Jefferies Group reaffirmed a “sell” rating and issued a $6.75 target price on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $11.00 target price on shares of Halozyme Therapeutics in a research note on Monday, June 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $15.68.

The firm’s market capitalization is $1.29 billion. The firm has a 50 day moving average price of $9.18 and a 200-day moving average price of $9.33.

A number of large investors have recently made changes to their positions in HALO. California Public Employees Retirement System increased its stake in shares of Halozyme Therapeutics by 10.2% in the fourth quarter. California Public Employees Retirement System now owns 255,600 shares of the biopharmaceutical company’s stock worth $4,430,000 after buying an additional 23,600 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of Halozyme Therapeutics by 5.4% in the fourth quarter. New York State Common Retirement Fund now owns 372,785 shares of the biopharmaceutical company’s stock worth $6,460,000 after buying an additional 18,940 shares during the last quarter. Finally, Nationwide Fund Advisors increased its stake in shares of Halozyme Therapeutics by 2.3% in the fourth quarter. Nationwide Fund Advisors now owns 69,817 shares of the biopharmaceutical company’s stock worth $1,210,000 after buying an additional 1,563 shares during the last quarter.

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.